Search research articles
Contact Us
Filters
Showing results (21-30 of 41) with videos related to
Page
of 5
Sort By:
Cancers
|
October 27, 2022
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis
Sandra M Swain, Harrison Macharia, Javier Cortes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2016
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3
Fabrice André, Sara Hurvitz, Angelica Fasolo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 4, 2022
Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
José Á García-Sáenz, Noelia Martínez-Jáñez, Ricardo Cubedo, et al.
The Lancet. Oncology
|
March 8, 2016
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli, Nicholas C Turner, Igor Bondarenko, et al.
The Oncologist
|
August 21, 2025
Intermediate endpoints as surrogates for long term outcomes in breast cancer adjuvant chemotherapy trials
Andrea Blasco, Sara López-Tarruella, Ander Urruticoechea, et al.
Cell Reports
|
November 29, 2018
Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines
Eniko Papp, Dorothy Hallberg, Gottfried E Konecny, et al.
International Journal of Cancer
|
April 10, 2025
Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies
José A García-Saenz, Gonzalo Spera, Marina Pollán, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2025
Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial
Peter A Fasching, Dennis Slamon, Zbigniew Nowecki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 23, 2019
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Siwen Hu-Lieskovan, Aaron Lisberg, Jesse M Zaretsky, et al.
The Lancet. Oncology
|
November 28, 2017
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
Sara A Hurvitz, Miguel Martin, W Fraser Symmans, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 41) with videos related to
Sort By:
Page
of 5
Cancers
|
October 27, 2022
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis
Sandra M Swain, Harrison Macharia, Javier Cortes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2016
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3
Fabrice André, Sara Hurvitz, Angelica Fasolo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 4, 2022
Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
José Á García-Sáenz, Noelia Martínez-Jáñez, Ricardo Cubedo, et al.
The Lancet. Oncology
|
March 8, 2016
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli, Nicholas C Turner, Igor Bondarenko, et al.
The Oncologist
|
August 21, 2025
Intermediate endpoints as surrogates for long term outcomes in breast cancer adjuvant chemotherapy trials
Andrea Blasco, Sara López-Tarruella, Ander Urruticoechea, et al.
Cell Reports
|
November 29, 2018
Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines
Eniko Papp, Dorothy Hallberg, Gottfried E Konecny, et al.
International Journal of Cancer
|
April 10, 2025
Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies
José A García-Saenz, Gonzalo Spera, Marina Pollán, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2025
Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial
Peter A Fasching, Dennis Slamon, Zbigniew Nowecki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 23, 2019
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Siwen Hu-Lieskovan, Aaron Lisberg, Jesse M Zaretsky, et al.
The Lancet. Oncology
|
November 28, 2017
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
Sara A Hurvitz, Miguel Martin, W Fraser Symmans, et al.
Page
of 5